What is MESO's current stock price?

MESO (Mesoblast Limited) is currently trading at $15.20 with a market cap of $1.96B.

What sector is Mesoblast Limited in?

Mesoblast Limited (MESO) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is MESO a good stock to buy?

Analysts have a Buy consensus on MESO with a price target of $11.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

MESO Mesoblast Limited

Healthcare

$15.20+1.47%ClosedMarket Cap: $1.96B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.31

P/S

123.72

EV/EBITDA

-39.77

DCF Value

$-2.66

FCF Yield

-2.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

-218.7%

Operating Margin

-572.0%

Net Margin

-500.5%

ROE

-14.0%

ROA

-10.0%

ROIC

-12.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$7.0M	$-27.1M	$—
FY null	$17.2M	$-102.1M	$—
Q3 null	$7.0M	$-27.1M	$—
Q2 null	$1.6M	$-24.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$11.50

Target (Median)

$11.50

Target Range

$11.00 - $12.00

2 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

JefferiesBuy

2025-11-25

JefferiesHold

2025-07-18

Trading Activity

Insider Trades

View All

COBLEY LYNETTE ELIZABETHdirector

SellWed Apr 29

COBLEY LYNETTE ELIZABETHdirector

SellWed Apr 29

George Gregorydirector, 10 percent owner:

BuyMon Apr 13

George Gregorydirector, 10 percent owner:

BuyMon Apr 13

George Gregorydirector, 10 percent owner:

BuyMon Apr 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.79

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Peers